Insights into the mechanism of methionine oxidation catalyzed by metal (Cu(2+), Zn(2+), and Fe(3+)) - amyloid beta (Abeta) peptide complexes: A computational study

Chemoselective Copper-Mediated Modification of Selenocysteines in Peptides and Proteins

Highly valuable bioconjugated molecules must be synthesized through efficient, chemoselective chemical modifications of peptides and proteins. Herein, we report the chemoselective modification of peptides and proteins via a reaction between selenocysteine residues and aryl/alkyl radicals. In situ radical generation from hydrazine substrates and copper ions proceeds rapidly in an aqueous buffer at near neutral pH (5-8), providing a variety of Se-modified linear and cyclic peptides and proteins conjugated to aryl and alkyl molecules, and to affinity label tag (biotin). This chemistry opens a new avenue for chemical protein modifications.

Potential molecular and graphene oxide chelators to dissolve amyloid-β plaques in Alzheimer's disease: a density functional theory study

The onset of Alzheimer's disease (AD) is caused by amyloid-β (Aβ) aggregation. Elevated levels of metals, specifically copper, zinc, iron, and aluminum, accumulate in senile Aβ; plaque deposits, disrupting normal brain homeostasis and cognitive functions. In this investigation, we studied the potential of several molecular and graphene oxide chelators to be used for future AD research and chelation therapy. To understand the interactions between selected metals (Cu, Zn, Fe, and Al), the Aβ peptide, and various potential metal chelating compounds, we implemented the density functional theory (DFT) method to calculate the binding energies of each metal-molecule complex. The binding energy of each metal-chelator complex was compared with that of the metal-Aβ compound to determine the chelation potential of the selected chelator. The potential chelating agents studied were 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone (INNHQ), 8-hydroxyquinoline-2-carboxaldehyde 2-furoyl hydrazone (HQFUH), quercetin, and graphene oxide (GO). Our calculated binding energies revealed that the HQFUH molecule holds direct ability to chelate copper, zinc, iron, and aluminum. In addition, the GO complex with a 12.5% oxygen concentration demonstrates aluminum chelation ability. Our results demonstrate that HQFUH and GO can be used in future AD drug development research and therapy to target toxic metal-Aβ interactions and reduce Aβ aggregation.

Comparative theoretical synthesis of high-energy explosive 1,4,5,8-tetranitro-1,4,5,8-tetraazadecalin

Reaction mechanisms were proposed in this study for the theoretical synthesis of high-energy 1,4,5,8-tetranitro-1,4,5,8-tetraazadecalin (TNAD). Corresponding computations were performed using density functional theory (DFT) and the Hartree Fock (HF) method with the same 6-31G(d,p) base function. Glyoxal and ethylenediamine were used as the raw materials and were placed into respective gaseous and solvated (water or ethanol) environments to proceed the condensation reaction to form the precursor 1,4,5,8-tetraazadecalin, which subsequently underwent four stages of nitro-group substitution to obtain the target TNAD compound. A whole reaction scheme closely related to the experimental processes was successfully constructed, and the corresponding energy barriers were estimated for each elementary reaction. The findings revealed that the overall activation energy by B3LYP/6-31G(d,p) calculation is 2660.4 kJ/mol, which is lower than the 2832.1 kJ/mol calculated by HF/6-31G(d,p) computation. Furthermore, the reaction has a lower overall energy barrier in the solvated environment than in the gaseous system, being 2389.6 kJ/mol in ethanol, 2428.7 kJ/mol in water and 2660.4 kJ/mol in the gaseous phase. The ethanol-solvated system is suggested to be the most suitable medium for the synthesis of TNAD.

Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease

Progressive cerebral deposition of the amyloid β-protein (Aβ) in brain regions serving memory and cognition is an invariant and defining feature of Alzheimer disease. A highly similar but less robust process accompanies brain aging in many nondemented humans, lower primates, and some other mammals. The discovery of Aβ as the subunit of the amyloid fibrils in meningocerebral blood vessels and parenchymal plaques has led to innumerable studies of its biochemistry and potential cytotoxic properties. Here we will review the discovery of Aβ, numerous aspects of its complex biochemistry, and current attempts to understand how a range of Aβ assemblies, including soluble oligomers and insoluble fibrils, may precipitate and promote neuronal and glial alterations that underlie the development of dementia. Although the role of Aβ as a key molecular factor in the etiology of Alzheimer disease remains controversial, clinical trials of amyloid-lowering agents, reviewed elsewhere in this book, are poised to resolve the question of its pathogenic primacy.

Simple and novel screening assay of natural antioxidants for Cu(II) ion/adrenaline-mediated oxidation of N-terminal amyloid beta by liquid chromatography/mass spectrometry

In the present study, a novel assay for screening inhibitors of Cu(II) ion/adrenaline-mediated oxidative modification of N-terminal amyloid beta (Abeta) peptides was developed using liquid chromatography with mass spectrometry (LC/MS). The physiological condition of Cu(II) ion/adrenaline in buffer (pH 7.4) at 37 degrees C for 90 min revealed a specific modification of N-terminal Abeta peptides, such as Abeta1-6, Abeta1-40, and Abeta1-42, using trypsin digestion and LC/MS detection of the modified Abeta peptide. When this oxidative modification of the shorter N-terminal Abeta1-6 was subjected to LC/MS, single charged ions from native peptide ([M+H]+, m/z 774) were observed at m/z 729 and 685, corresponding to a decrease in mass of 45 and 89 Da, respectively, as compared with the original peptide. To determine the effect of specific antioxidants, a screening assay to find inhibitors of Cu(II) ion/adrenaline-mediated oxidation was developed based on the response ratio of m/z 685 to 774. LC/MS detection of the modified peptides allowed us to identify antioxidants that inhibit oxidative modification of Abeta1-6 model peptide. The oxidative modification of Abeta1-6 was inhibited by curcumin but not an isoflavone or catechin mixture or saponin or capsaicin, revealing a clear difference between antioxidants that inhibit oxidative modification and other antioxidants. This novel assay may allow for the identification of antioxidants that protect against oxidative modification of Abeta and other proteins related to oxidative stress by adrenaline and Cu(II) ions under normal physiologic conditions.